C-Path receives FDA qualification for SMDDS

(Critical Path Institute (C-Path)) C-Path's Patient-Reported Outcome (PRO) Consortium announces its first clinical outcome assessment qualification from FDA, for the Symptoms of Major Depressive Disorder Scale (SMDDS). The SMDDS, a 16-item PRO measure developed by the PRO Consortium's Depression Working Group, captures the core symptoms of major depressive disorder (MDD) that matter most to patients. Drug developers are encouraged to discuss with FDA inclusion of this novel instrument in their MDD drug development programs.

from EurekAlert! - Social and Behavioral Science http://ift.tt/2B8ZAmg